Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 26
A short history of TB-500
TB-500 (thymosin beta-4) was first sequenced in 1981. Four decades on, it has no approved human use and only one controlled trial, in eye disease.
GH-IGF1 peptides: the clinical evidence gap
A 2026 Frontiers review maps the gap between trial data and self-administration practice for CJC-1295, ipamorelin, and related GH-axis peptides.
GLP-1 agonists in adolescent obesity: NMA
A July 2026 network meta-analysis found semaglutide 2.4 mg led on weight reduction in adolescents with obesity. Most comparisons were indirect.
GLP-1 drugs in pediatric obesity
Liraglutide and semaglutide carry regulatory approval for adolescents with obesity. A 2026 review maps what the trials found and what gaps remain.
Semaglutide lowers blood eosinophil counts
A real-world study of 371 adults found semaglutide cut blood eosinophil counts, with a larger effect in non-obese participants.
How long before incretins help in HFpEF?
A 2026 meta-analysis finds semaglutide and tirzepatide cut worsening HF events in HFmrEF/HFpEF, with sustained benefit from roughly five months onward.
Incretin drugs for T2D: 2026 NMA results
A 2026 network meta-analysis of 102 trials and 98,693 T2D patients ranked tirzepatide first for glycaemic control and retatrutide first for weight loss.
PT-141: reconstituting part of a vial
Vyleesi is a pre-filled autoinjector, not a powder. Research-grade PT-141 cakes are not evenly distributed, so splitting gives an unknown concentration.
Selank headaches: what the research shows
Some users report headaches when starting Selank. Here is what the published research says about the peptide's neurotransmitter effects.
How semaglutide works: the GLP-1 receptor
Semaglutide binds the GLP-1 receptor in the pancreas, brain, and gut. Here is what happens at each site.
Semaglutide side effects: what trials show
The STEP and SUSTAIN programmes documented semaglutide adverse events at scale. Here is what the data show, from GI effects to the thyroid boxed warning.
Semaglutide WADA status
Semaglutide is not on the WADA prohibited list and requires no TUE. WADA is monitoring GLP-1 agonists. Here is what competing athletes need to know.